Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05867329 · ClinicalTrials.gov registry record · Phase 4
Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis
A Phase 4 study of Ulcerative Colitis Acute, sponsored by Berinstein, Jeffrey.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 162
- Enrollment target
- 1
- Study location
NCT05867329: Recruiting Phase 4 study of Ulcerative Colitis Acute, sponsored by Berinstein, Jeffrey.
NCT05867329 is a Phase 4 study of Ulcerative Colitis Acute that is actively recruiting participants, run by Berinstein, Jeffrey. The registered enrollment target is 162 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05867329, a Phase 4 study of Ulcerative Colitis Acute, is actively recruiting participants, sponsored by Berinstein, Jeffrey.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 162 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this trial is to create personalized treatments for each patient admitted to the hospital with acute severe ulcerative colitis (ASUC). The study will test the feasibility and acceptability of these treatment strategies among patients and physicians so that the study team can later do a larger trial to test whether the medication treatment pathways help patients avoid colectomy while ensuring patient's are safe.
Primary Outcome
Target ≥60%
Conditions Studied
Interventions
- DRUG Cyclosporine Injection (IV)
- DRUG Cyclosporine Oral Product
- DRUG Upadacitinib Extended Release Oral Tablet
- DRUG Intravenous Methylprednisolone
- DRUG Prednisone Oral Product
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2023-09-30 |
| Est. Completion | 2026-05 |
| Phase | Phase 4 |
What NCT05867329 shows while recruiting
NCT05867329 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Ulcerative Colitis Acute appearing as the primary indexed condition, and to 5 interventions - of which Cyclosporine Injection (IV) is the first listed.
NCT05867329 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05867329 about?
NCT05867329 is a clinical study titled "Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis". The goal of this trial is to create personalized treatments for each patient admitted to the hospital with acute severe ulcerative colitis (ASUC). The study will test the feasibility and acceptability of these treatment strategies among patients and physicians so that the study team can later do a l...
What is the current status of trial NCT05867329?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 162 participants. The study started on 2023-09-30. Estimated completion is 2026-05.
What conditions does trial NCT05867329 study?
This clinical trial studies the following conditions: Ulcerative Colitis Acute.
What interventions are being tested in trial NCT05867329?
The interventions under investigation include: Cyclosporine Injection (IV) (DRUG), Cyclosporine Oral Product (DRUG), Upadacitinib Extended Release Oral Tablet (DRUG), Intravenous Methylprednisolone (DRUG), Prednisone Oral Product (DRUG).
Who is sponsoring clinical trial NCT05867329?
This trial is sponsored by Berinstein, Jeffrey, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05867329 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis Acute
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05867329's enrollment target sits among peer trials
162 503rd of 2000 higher than 1,496 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI